International Stem Cell Corp
internationalstemcell.comInternational Stem Cell Corp (OTC QX: ISCO) is a biotechnology company that develops human stem cell-based therapies and manufactures human cell culture products for research use. Revenue comes from two activities: commercial sales of cell culture products through its LCT subsidiary, and advancement of proprietary therapeutic programs funded by equity and debt financing rather than product royalties or partnerships. LCT produces over 200 human cell culture products, including frozen primary cells, stem cells, and growth media, sold to pharmaceutical, academic, and government research organizations. On the therapeutic side, ISCO's most advanced program is ISC-hpNSC, parthenogenetic stem cell-derived neural stem cells for Parkinson's disease, which completed Phase 1 enrollment with 12 subjects as of April 2019; full Phase 1 results are expected in the second half of 2026. The company holds exclusive licenses from Astellas Pharma covering parthenogenesis, single blastomere, and other stem cell technologies. ISCO operates from San Diego, California, carries an accumulated stockholders' deficit, and has never paid a cash dividend as of the 10-K filed March 30, 2026.
Products & Services
LCT subsidiary: over 200 human cell culture products including frozen primary cells, stem cells, and optimized growth media/reagents, including Xeno-free formulations. Therapeutic pipeline: ISC-hpNSC (parthenogenetic neural stem cells) for Parkinson's disease in Phase 1; stroke program also referenced. Proprietary parthenogenesis-based pluripotent stem cell platform with licensed SCNT, iPS, and single blastomere technologies.
Revenue Model
Commercial product sales from LCT's human cell culture catalog (cells, media, reagents) sold transactionally to research organizations; therapeutic programs are pre-revenue and funded through equity and debt issuance.
Customers & Markets
Research scientists at pharmaceutical companies, academic institutions, and government research organizations purchasing cell culture products. Therapeutic end market targets Parkinson's disease patients and potentially stroke patients, with no approved product as of the filing date.
Geographic Exposure
Headquartered and manufactured in San Diego, California. LCT products sold domestically and internationally per the 10-K filed March 30, 2026; no further geographic revenue breakdown supported by the filing excerpts.
Financial Snapshot
Loading...
